• Explore /
  • Poster
  • / Sintilimab plus oxaliplatin/capecitabine (CapeOx) as neoadjuvant therapy in patients with locally advanced, resectable gastric (G)/esophagogastric junction (GEJ) adenocarcinoma.

Sintilimab plus oxaliplatin/capecitabine (CapeOx) as neoadjuvant therapy in patients with locally advanced, resectable gastric (G)/esophagogastric junction (GEJ) adenocarcinoma.

Abstract Poster

Authors

null

Haiping Jiang

Department of Medical Oncology, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China

Haiping Jiang , Xiongfei Yu , Mei Kong , Zhiming Ma , Donghui Zhou , Weibing Wang , Haohao Wang , Ning Li , Haiyong Wang , Kuifeng He , Zhongqi Li , Yiming Lu , Jing Zhang , Kui Zhao , Yafei Zhang , Nong Xu , Lisong Teng

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session: Esophageal and Gastric Cancer

Track

Esophageal and Gastric Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT04065282

Citation

J Clin Oncol 39, 2021 (suppl 3; abstr 211)

DOI

10.1200/JCO.2021.39.3_suppl.211

Abstract #

211

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Ning Li

First Author: Ying Liu

First Author: Hongli Li

First Author: Ning Li